Hexarelin stands as the most potent synthetic growth hormone-releasing peptide (GHRP) ever developed, demonstrating growth hormone release activity at doses 10-fold lower than its predecessor GHRP-6. This hexapeptide (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) appears to activate the ghrelin receptor (GHSR1a) with an affinity that fundamentally differs from natural growth hormone-releasing hormone, suggesting a distinct molecular pathway that researchers are only beginning to understand.
Hexarelin Entity Profile
| Compound Name: | Hexarelin (Examorelin) |
| CAS Number: | 140703-51-1 |
| Molecular Weight: | 887.04 Da |
| Sequence: | His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Primary Mechanism: | GHSR1a receptor agonist (EC50: ~0.2 nM) |
| Secondary Mechanism: | CD36 scavenger receptor activation |
| Key Researchers: | Ghigo E., Bowers C.Y., Deghenghi R. |
| Related Entities: | GHRP-6, GHRP-2, Ghrelin, Ipamorelin |
| Half-life: | 70 minutes (plasma) |
Molecular Mechanism and Receptor Interaction
Hexarelin's synthetic structure incorporates two critical modifications that distinguish it from natural GHRPs: the D-2-methyl-tryptophan at position 2 and the D-phenylalanine at position 6. These modifications appear to create a conformational lock that increases receptor binding affinity by approximately 30-fold compared to GHRP-6, while simultaneously extending the peptide's half-life through enhanced proteolytic resistance.1
Research indicates that hexarelin binds to the GHSR1a receptor with a Kd of approximately 0.7 nM, triggering a phospholipase C-mediated cascade that elevates intracellular calcium concentrations within 45 seconds of administration. This rapid activation translates to growth hormone release that peaks at 15-30 minutes and maintains elevated levels for up to 6 hours in research models.2
Comparative Potency Analysis
In direct comparison studies, hexarelin demonstrates growth hormone-releasing activity at doses of 0.5-1.0 μg/kg, while ipamorelin requires 10-30 μg/kg to achieve similar responses. This 10-30 fold potency difference suggests that hexarelin's molecular modifications create a more efficient receptor activation profile, potentially through enhanced receptor occupancy time or increased signal transduction efficiency.3
Growth Hormone Axis Modulation
Hexarelin appears to stimulate growth hormone release through multiple pathways simultaneously. Beyond direct GHSR1a activation, research suggests the peptide may influence hypothalamic GHRH neurons and potentially modulate somatostatin release, creating what researchers term a "synchronized growth hormone pulse" that more closely mimics physiological patterns than single-pathway stimulation.4
Laboratory studies indicate that hexarelin administration results in a 3.5-fold increase in IGF-1 concentrations within 24 hours, accompanied by sustained elevation for 48-72 hours. This extended IGF-1 response pattern differs markedly from the acute spikes observed with direct growth hormone administration, suggesting a more sustained anabolic signaling cascade.5
Desensitization Resistance Properties
Unlike continuous GHRH stimulation, hexarelin demonstrates remarkable resistance to receptor desensitization in research protocols. Studies spanning 28 days of continuous administration show maintained growth hormone responses at approximately 85% of initial levels, compared to 40-50% reduction typically observed with other GHRP compounds. This resistance appears linked to the peptide's unique receptor binding kinetics and potential allosteric modulation effects.6
Cardioprotective Research Applications
Beyond growth hormone release, hexarelin research has revealed significant cardioprotective properties that appear independent of the growth hormone axis. The peptide demonstrates direct binding to cardiac tissue with high affinity, suggesting the presence of cardiac-specific GHSR1a populations or alternative receptor targets.7
In ischemia-reperfusion research models, hexarelin pretreatment appears to reduce infarct size by 40-45% when administered 30 minutes prior to ischemic insult. The mechanism appears to involve rapid activation of survival kinase pathways, including Akt and ERK1/2, leading to enhanced mitochondrial bioenergetics and reduced apoptotic signaling.8
Cardiac Metabolism and Function
Research indicates that hexarelin may directly influence cardiac metabolism through enhanced glucose uptake and fatty acid oxidation. Studies show increased GLUT4 translocation in cardiomyocytes within 2 hours of hexarelin exposure, accompanied by a 25% increase in ATP production and improved contractile efficiency metrics.9
Research Protocol Considerations
Hexarelin's high potency requires careful dose optimization in research applications. Standard research protocols utilize doses ranging from 0.1-2.0 μg/kg, with most growth hormone studies employing 1.0 μg/kg administered subcutaneously. For cardioprotection research, higher doses (2-5 μg/kg) are typically required to achieve therapeutic tissue concentrations.10
The peptide demonstrates excellent stability in research conditions when stored at -20°C in lyophilized form. Once reconstituted with bacteriostatic water, solutions maintain activity for up to 30 days when refrigerated, though daily preparation is recommended for critical research applications. For detailed reconstitution protocols, see our peptide reconstitution guide.
Analytical Considerations
Hexarelin analysis requires specialized HPLC methods due to the peptide's lipophilic properties conferred by its modified tryptophan residues. Research laboratories typically employ C18 reverse-phase columns with acetonitrile-water gradients for purity assessment. Mass spectrometry confirmation should target the molecular ion at m/z 887.47 [M+H]+.
Comparative Research Applications
In growth hormone deficiency research models, hexarelin demonstrates superior efficacy compared to CJC-1295 or natural GHRH analogs. The synthetic peptide's ability to stimulate growth hormone release in the presence of elevated somatostatin makes it particularly valuable for studying pathological conditions where natural GH pulsatility is disrupted.
For researchers investigating the intersection of growth hormone signaling and cardiac function, hexarelin offers unique advantages through its dual mechanism profile. This makes it particularly relevant for aging research, where both growth hormone decline and cardiovascular dysfunction represent primary research targets.
Frequently Asked Questions
How does Hexarelin differ from other GHRPs?
Hexarelin demonstrates 10-fold higher potency than GHRP-6 and 2-3 fold higher potency than GHRP-2 in growth hormone release assays. Unlike other GHRPs, Hexarelin also activates CD36 scavenger receptors, providing cardioprotective effects independent of its growth hormone-releasing properties [5].
What is Hexarelin's mechanism of action?
Hexarelin primarily activates the ghrelin receptor (GHSR1a) in the hypothalamus and pituitary, triggering growth hormone release. Secondary mechanisms include CD36 receptor activation in cardiac tissue and potential modulation of IGF-1 expression in peripheral tissues [6].
What are Hexarelin's research applications?
Primary research areas include growth hormone deficiency studies, cardiac protection research, muscle wasting investigations, and metabolic disorder models. Studies focus on its dual GHSR1a/CD36 receptor activity profile [7].
How should Hexarelin be reconstituted for research?
Reconstitute lyophilized Hexarelin with bacteriostatic water at 1-2 mg/mL concentration. Store reconstituted solution at 2-8°C for up to 14 days or -20°C for extended storage. Avoid freeze-thaw cycles [8].
What dosing ranges are used in research studies?
Research dosing typically ranges from 1-2 mcg/kg in animal models, with human studies utilizing 2-4 mcg/kg doses. Peak growth hormone response occurs at approximately 1 mcg/kg with diminishing returns at higher doses due to receptor desensitization [9].
Future Research Directions
Current research focuses on elucidating hexarelin's cardiac-specific mechanisms and potential therapeutic applications beyond growth hormone modulation. Studies investigating the peptide's effects on neuroplasticity and neuroprotection show preliminary promise, with early data suggesting BDNF upregulation and enhanced synaptic plasticity in hippocampal research models.
The development of hexarelin analogs with tissue-specific targeting represents an active area of research, with investigators working to separate the peptide's growth hormone-releasing properties from its cardioprotective effects for more precise research applications.
Important Notice: This content is for educational and research purposes only. Hexarelin is not approved for human consumption and should only be used in qualified research settings following appropriate institutional protocols. Researchers should consult relevant ethical guidelines and safety protocols before conducting studies with this compound.
